Figures
- FIGURE 1
Cost-effectiveness acceptability curve. t-PA: tissue plasminogen activator.
Tables
- TABLE 1
Unit costs
Unit cost EUR Source Study medications, per dose Alteplase 10 mg 164 British National Formulary Pulmozyme 2.5 mg 19 British National Formulary Initial hospital stays, per day Initial stay, nonsurgery 502 NHS Reference Costs Initial stay, surgery 955 NHS Reference Costs Subsequent admissions Hospital stay# 756# NHS Reference Costs Individual hospitalisation costs were applied in the main analysis. Based on the British National Formulary (www.bnf.org) and NHS Reference Costs [21]. #: weighted average for the 37 different reasons patients were readmitted during study follow-up.
- TABLE 2
Number of days in hospital over the 12-month follow-up period
t-PA DNase Placebo t-PA–DNase Subjects 44 41 48 45 Initial hospital stay Number of days, nonsurgical 14.48±20.21 22.59±58.74 23.65±54.90 11.43±9.31 Number of days, surgical 2.05±9.30 5.66±18.07 1.17±4.36 0.24±1.15 Number of days, total 16.52±22.79 28.24±61.41 24.81±56.11 11.78±9.43 Subsequent hospital stays Patients with one or more subsequent admissions 3 (7) 1 (2) 4 (8) 1 (2) Number of days 0.75±2.96 0.75±4.83 1.38±6.54 0.16±1.04 Total hospital stays Number of days 17.27±24.79 29.00±62.01 26.19±56.66 11.93±9.57 Data are presented as n, mean±sd or n (%). t-PA: tissue plasminogen activator.
- TABLE 3
Mean costs and outcomes over the 12-month follow-up period
t-PA DNase Placebo t-PA–DNase Subjects 44 41 48 45 Costs EUR Trial medications 986 227 0 1213 Initial hospital stay, nonsurgical 7155±9991 11 164±27 892 11 687±27 133 5701±4604 Initial hospital stay, surgical 1953±8874 5401±17 247 1113±4159 234±1098 Subsequent admissions 511±2026 1065±6820 682±2865 102±682 Total costs 10 605±15 413 17 856±34 861 13 483±28 798 7248±4922 Life-years gained 0.988±0.081 0.923±0.228 0.969±0.147 0.969±0.153 Cost-effectiveness of placebo versus trial interventions ICER t-PA dominant Placebo dominant NA EUR 1.6 billion Probability placebo cost-effective 0.24 0.81 NA 0.04 Data are presented as n or mean±sd. t-PA: tissue plasminogen activator; ICER: incremental cost-effectiveness ratio; NA: not applicable.
- TABLE 4
Cost-effectiveness of treatments for pleural infection at 12 months
Incremental costs EUR (95% CI) Incremental life-years (95% CI) Incremental cost-effectiveness ratio Probability of intervention being cost-effective# t-PA–DNase 0.86 t-PA 3357 (−335–8114) 0.019 (−0.025–0.062) EUR 178 166 0.12 Placebo 2878 (−4280–10 874) −0.019 (−0.061–0.020) t-PA both more effective and less costly 0.03 DNase 4373 (−6700–15 940) −0.045 (−0.116–0.016) t-PA both more effective and less costly 0.001 t-PA: tissue plasminogen activator. #: assuming a cost-effectiveness threshold of GBP 30 000 (EUR 34 220) per life-year gained.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
ERJ-01550-2018_Online supplementary appendix ERJ-01550-2018_Online_supplementary_appendix
